|
|
[url]http://www.medpagetoday.com/InfectiousDisease/URItheFlu/28107[/url]
Most importantly to those of us here at FAS:QuoteAlthough the guidance is largely similar to that from previous seasons, additional updates include the availability of the intradermal formulation of Fluzone -- which was approved by the FDA in May -- and new recommendations regarding vaccination in individuals with egg allergy -- which were discussed at one of ACIP's meetings in June.
Included in the recommendations for vaccination in the presence of egg allergy:
•Those with a history of hives only after exposure to egg can receive influenza vaccine, but should receive the trivalent inactivated vaccine (TIV) rather than the live attenuated influenza vaccine (LAIV), should be vaccinated by a healthcare provider who is familiar with potential manifestations of egg allergy, and should be observed for at least 30 minutes following administration.
•People who have had more severe allergic reactions to egg should be referred to a physician with expertise in the management of allergies for further risk assessment.
•The vaccine should be administered in settings equipped for the rapid recognition and treatment of anaphylaxis.
The authors noted that a previous severe allergic reaction to influenza vaccine, regardless of the component causing the reaction, is a contraindication to getting the vaccine.
This is a bit of a pull-back from last year's "It's fine for EVERYONE, even those with egg allergy" advice. :-/ Hopefully many allergists will continue offering testing and split dosing with low-egg-protein lots.